Neil Kumar, Chief Executive Officer and Director of BridgeBio Pharma, Inc. (NASDAQ:BBIO), filed a Form 4 on August 20, 2026, reporting sales of BridgeBio common stock on August 18 and 19, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Direct sales on August 18: Neil Kumar disposed of a combined 34,980 shares of common stock directly, across four tranches with weighted average prices ranging from $81.1494 to $83.7732 per share.
  • Indirect sales on August 19: 10,000 shares were disposed of indirectly through the Kumar Haldea Family Irrevocable Trust, at weighted average prices ranging from $83.8588 to $85.65 per share.
  • 10b5-1 plan: All sales were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 13, 2026.
  • Remaining direct ownership: Following the reported transactions, Kumar directly beneficially owned 243,327 shares of common stock.
  • Indirect holdings: Kumar also holds shares indirectly through the Kumar Haldea Family Irrevocable Trust (505,686 shares), the Kumar Haldea Revocable Trust (3,568,447 shares), and the NK 2026 GRAT (750,000 shares), as co-trustee or trustee of each.
  • Beneficial ownership disclaimer: According to the filing, Kumar "disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein" for shares held through the trusts.

BridgeBio CEO Neil Kumar's Share Sales and Beneficial Ownership After August 2026 Transactions

According to the filing, Neil Kumar, who serves as Chief Executive Officer and Director of BridgeBio Pharma, Inc., sold a total of 34,980 shares of common stock directly on August 18, 2026. These sales were broken into four separate tranches: 1,900 shares at a weighted average price of $81.1494 (range $80.54 to $81.53), 17,279 shares at $82.2104 (range $81.62 to $82.61), 14,602 shares at $82.9922 (range $82.62 to $83.61), and 1,199 shares at $83.7732 (range $83.65 to $83.90). Following these transactions, the filing reports his direct beneficial ownership at 243,327 shares.

On August 19, 2026, the filing reports that 10,000 additional shares were sold indirectly through the Kumar Haldea Family Irrevocable Trust, of which Kumar is a co-trustee. Those sales occurred in three tranches: 8,100 shares at a weighted average price of $83.8588 (range $83.34 to $84.31), 1,800 shares at $84.6867 (range $84.35 to $85.21), and 100 shares at $85.65. After those transactions, the trust's reported holdings stood at 505,686 shares.

The filing also discloses that Kumar holds shares indirectly through the Kumar Haldea Revocable Trust (3,568,447 shares) and the NK 2026 GRAT (750,000 shares), described as "a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant." The filing notes that Kumar disclaims beneficial ownership of trust-held shares except to the extent of any pecuniary interest. All reported sales were made under a Rule 10b5-1 plan adopted on May 13, 2026, the filing states.

What Was Disclosed

The Form 4 filed August 20, 2026 reports that BridgeBio Pharma CEO Neil Kumar sold a combined 44,980 shares of common stock directly and indirectly on August 18 and 19, 2026, all under a pre-adopted Rule 10b5-1 plan, with direct post-transaction ownership of 243,327 shares.